Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29230314 | 0.76 | ALDH1A1 (0.33) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL29230313 | 0.76 | ALDH1A1 (0.33) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| Hydrochloric Acid SCHEMBL29230339 | 0.74 | ALDH1A1 (0.32) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| Hydrochloric Acid SCHEMBL29230337 | 0.74 | ALDH1A1 (0.32) | ALDH1A1MAPTPTGS1SLC7A5TP53 | |
| SCHEMBL4745235 | 0.72 | ALDH1A1 (0.31) | ALDH1A1MAPTPTGS1 | |
| SCHEMBL2106917 | 0.72 | ALDH1A1 (0.32) | ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL3993907 | 0.70 | TDP1 (0.31) | TSHR | |
| SCHEMBL8702792 | 0.70 | FDPS (0.34) | ALDH1A1MAPTPTGS1CA2MAPK1 | |
| SCHEMBL9611561 | 0.70 | FDPS (0.34) | ALDH1A1MAPTPTGS1CA2MAPK1 | |
| SCHEMBL755837 | 0.70 | FDPS (0.34) | ALDH1A1MAPTPTGS1CA2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885MAPT 1956/4885PTGS1 1977/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885MAPT 1956/4885PTGS1 1977/4885 |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885MAPT 1956/4885PTGS1 1977/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | ALDH1A1 3628/4885MAPT 1956/4885PTGS1 1977/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | ALDH1A1 4627/4885MAPT 1123/4885PTGS1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.